Executive Director, US Portfolio Analytics
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
Reporting directly to the Vice President, US Analytics & Insights, the Executive Director, US Portfolio Analytics will lead the portfolio-wide analytics capabilities that enable data-driven commercial decision-making across Revolution Medicines’ US business. This leader will be accountable for Field Analytics, Market Access Analytics, Data Strategy & Governance, Omnichannel Analytics, and Dashboards, ensuring scalable, integrated capabilities that support launch readiness, commercialization, and perfor
